Description
Created On: 2020-07-15
Record Count: 11
Primary Industries
- Drugs
- Disease
- Therapeutic
- Cancer
- Pain
- Technical Know How
- Delivery
- Pharmaceuticals
- Diagnostic
- Monitoring
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 257486
Licensor grants a non-exclusive, worldwide sublicense to make or use any analytical reference standards, intermediate or metabolite of the Compound or Product which may be claimed in Patents limited solely to making or using the Compound or Product.
Licensee represents and warrants that during the term of this Sub license Agreement, neither it, an Affiliate or a Sublicensee shall license, develop, have developed, manufacture, have manufactured, sell or have sold any of the following compounds or products classified as an atypical antipsychotic: i.e. Olanzapine, Sertindole, Seroquel, Ziprasadone, Risperidone.
Compound shall mean the chemical compound known as Iloperidone, whose specific chemical name is 1 -[ 4-(3-[ 4-(6-fluoro-l ,2-benzisoxazol-3-y 1)-1-piperidinyl]propoxy ]-3-methoxyphcnyl]ethanone, including any salts, hydrates, solvates, and/or stereoisomers thereof, and only the metabolites listed hereto, including any salts, hydrates, solvates and/or stereoisomers of such metabolites.
IPSCIO Record ID: 257485
The Swiss Licensor grants an Exclusive sublicense in the Field under the Patents licensed to Licensor or its Affiliates and an Exclusive license in the Field under the Patents, except for the Biomarker Patent, owned by Licensor or its Affiliates, an Exclusive sublicense and license, as applicable, in the Field under the Know-How and a non-exclusive license in the Field under the Patent owned by Licensor covering the biomarker, in each case, to research, develop, have developed, make, have made, use, import, sell, offer for sale and have sold the Compound and Product in the ROW Territory,
Licensor grants a non-exclusive, ROW Territory sublicense to make or use any analytical reference standards, intermediate or metabolite of the Compound or Product, not listed, which may be claimed in Patents in the ROW Territory limited solely to making or using the Compound or Product.
Product shall mean any bulk or finished pharmaceutical composition containing the Compound as a pharmaceutically active ingredient for use in the Field.
Depot Formulation shall mean any extended-release, injectable formulation of the Compound.
The parties acknowledge and agree that Products sold within the United States will be sold only under the trademark FANAPTâ„¢.
IPSCIO Record ID: 257706
Licensor grants the Swiss Licensee an Exclusive license in the Field under the Licensor Know-How to research, develop, have developed, make, have made, use, import, sell, offer for sale and have sold the Compound and Product in the U.S./Canadian Territory.
Licensor grants an exclusive right and license, with the right to grant sublicenses, to use the Licensor Trademark in the U.S./Canadian Territory in connection with the manufacture, use, import and commercialization of Products in the U.S./Canadian Territory; and, a nonexclusive license to use the Licensor Trademarks, other than the Licensed Trademark in the U.S./Canadian Territory in connection with the manufacture and commercialization of Products, such license to include the right to distribute Products in the U.S./Canadian Territory with packaging that bears the Licensor Trademarks; and an exclusive right and license, with the right to grant sublicenses, to use the Licensor Copyrights in connection with the commercialization of the Products in the U.S./Canadian Territory.
Product shall mean any bulk or finished pharmaceutical composition containing the Compound as a pharmaceutically active ingredient for use in the Field.
Depot Formulation shall mean any extended-release, injectable formulation of the Compound.
The trademark and domain names all relate to FANAPTâ„¢ and Iloperidone.
Iloperidone, commonly known as Fanapt and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.
IPSCIO Record ID: 166962
Licensor grants a non-exclusive, worldwide license to make or use any analytical reference standards, intermediate or metabolite of Compound or Product not listed hereto which may be claimed.
Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.
IPSCIO Record ID: 223128
Compound shall mean the compound currently identified by Licensors as NDD-094 or isomers or epimers thereof and any metabolites and salts thereof and more particularly described Licensor Patents shall mean those Patents Controlled by Licensor claiming Compound, Product, or their metabolites or any formulation of Compound, processes, uses and intermediates of the foregoing.
Licensor Know-How shall mean any proprietary or nonproprietary information specific to the Compound or Product within the Field of Use and of a confidential nature necessary or useful for the manufacture, preparation or development of the Compound or Product Controlled by Licensors during the term of this Agreement and shall include, without limitation, data, knowledge and information., including chemical, stability, pharmacological, toxicological, pre-clinical, clinical and manufacturing data, samples, documentation, analytical standards, and gene expression data.
Patents – United States
5,635,521 – Imidazolylmethyl-pyridines
5,856,343 – Imidazolylmethyl-pyridines used for senile dementia
Iloperidone is an atypical antipsychotic for the treatment of schizophrenia.
IPSCIO Record ID: 52353
Patents include:
US – 07/354,411 abandoned; US – 07/456,790 abandoned; EP – 90/09208.0, granted 0 402 644 B1; Austria – 55770/90, issued 640,653; Canada – 2,017,193-6; China – 90103721.4; Czech Republic – 2425-90; Finland – 902449; Hungary – 3090/90; Israel – 94425; Japan – 127090/90, issued 1931594; Korea – 90/7102; Mexico – 20787; Norway – P902214, 177301; Philippines – 40530; Poland – P-285247, 163965; Russia – 4743876/04; US – 07/619,825 continuation abandoned; US – 07/944,705 continuation abandoned; US – 07/788,269 abandoned; US – 07/969,383 issued 5,364,866; PCT – 92/09276 WO/93/09102; EP – 92/924151.1; EP (PT) – 92/118992.5; Austria – 30570/92; Belarus – 1715; Canada – 2,121,253; Czech Republic – PV 1102-94; Finland – 942052; Georgia – 001977; Hungary – P9401316; Israel – 103622; Japan – 5-508591; Korea – 94-701524; Kazakhstan – 941593.1; Mexico – 926370; Norway – 941647; New Zealand – 245006; Philippines – 45259; Poland – P-303452; Romania – 9400761; Russia – 94028105.04; Slovak Republic – PV 0456-94; Taiwan – 81108831; Uzbekistan – 9500706.1; US – 08/144,265 abandoned; US – 08/309,395 pending; US – 08/329,000 allowed; US – 08/468,611 pending; PCT – 94/12054 WO95/11680; Canada – 94/12054; China – 94194302.X; Czech Republic – PV 1238-96; Hungary – P/P 00576 06/29/95, 211,853 11/05/95 06/29/2015; Indonesia – 951058; Ireland – 94/12054; Israel – 111,498; Japan – 512724/1995; Korea – 96-702162; Mexico – 94 8405;Norway – p961686; New Zealand – 275941; Poland – P314135; Romania – 96-00888; Russia – 96110214; Taiwan – 83110396; South Africa – 95/2653
IPSCIO Record ID: 182112
“TR-Beta Compounds†means Metabasis’ MB07811 and MB10866 compounds, and any other compounds comprised by the TR-Beta Patents, and any salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers, polymorphs, and derivatives of such compounds.
IPSCIO Record ID: 233451
The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.
The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.
The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.
Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.
IPSCIO Record ID: 182114
Diacylglycerol O-acyltransferase 1 is an enzyme that in humans is encoded by the DGAT1 gene.
Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.
IPSCIO Record ID: 275417
— an exclusive license, with the right to grant sublicenses, under Licensor’s right, title and interest in and to the Licensor Patents, the Licensor Know-How, the Joint IP, the Joint Patents and the New IP owned or Controlled by Licensor specifically for and limited to Develop the Product in the Licensee Territory for the Indication, and
— an exclusive license, with the right to grant sublicenses, under Licensor’s right, title and interest in and to the Licensor Patents, the Licensor Know-How, the Joint IP, the Joint Patents and the New IP owned or Controlled by Licensor to Manufacture, have Manufactured and Commercialize the Product in the Licensee Territory for the Indication.
IPSCIO Record ID: 239024
Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.
Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.
